BridgeBio Pharma, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing and delivering transformative medicines to patients with genetic diseases and cancers. The company’s core products and services include the research, development, and commercialization of novel drug candidates targeting genetic disorders and oncology indications. BridgeBio’s portfolio encompasses multiple clinical and preclinical programs across areas such as rare diseases, oncology, and precision medicine, featuring therapies in pipeline development as well as marketed products. BridgeBio operates primarily in the United States but also engages in global clinical trials and partnerships to expand its reach. Founded in 2015 and headquartered in Palo Alto, California, the company leverages its drug development expertise through subsidiaries and strategic alliances with academic institutions, pharmaceutical companies, and biotechnology firms. Recent major company developments include significant funding rounds to advance its pipeline programs; strategic partnerships to enhance its research capabilities; acquisitions aimed at broadening its therapeutic areas and bolstering its technology platforms; and the launch of new investigational drugs targeting underserved genetic conditions. These moves have reinforced BridgeBio’s commitment to advancing precision medicine and expanding its impact in the rare disease and oncology markets. The company continues to evolve its pipeline with a focus on rapid clinical development and commercialization of targeted therapies to improve patient outcomes.
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn't a Slam Dunk
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
BridgeBio to Participate in May and June Investor Conferences
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know